Last reviewed · How we verify
Aatezolizumab plus Bevacizumab
Atezolizumab blocks PD-L1 to enhance immune response while bevacizumab inhibits VEGF to reduce tumor angiogenesis, combining immunotherapy with anti-angiogenic therapy.
Atezolizumab blocks PD-L1 to enhance immune response while bevacizumab inhibits VEGF to reduce tumor angiogenesis, combining immunotherapy with anti-angiogenic therapy. Used for Hepatocellular carcinoma (Phase 2), Advanced or metastatic solid tumors (Phase 2).
At a glance
| Generic name | Aatezolizumab plus Bevacizumab |
|---|---|
| Also known as | Ticentriq plus Avastin |
| Sponsor | Tae Won Kim |
| Drug class | PD-L1 inhibitor + VEGF inhibitor combination |
| Target | PD-L1 and VEGF |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Atezolizumab is a PD-L1 inhibitor that restores anti-tumor T-cell immunity by blocking the PD-L1/PD-1 checkpoint. Bevacizumab is a VEGF inhibitor that starves tumors of blood supply and may enhance immune infiltration. The combination leverages both immune checkpoint inhibition and anti-angiogenic mechanisms to improve anti-tumor efficacy.
Approved indications
- Hepatocellular carcinoma (Phase 2)
- Advanced or metastatic solid tumors (Phase 2)
Common side effects
- Fatigue
- Hypertension
- Diarrhea
- Immune-related adverse events (pneumonitis, hepatitis)
- Bleeding
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aatezolizumab plus Bevacizumab CI brief — competitive landscape report
- Aatezolizumab plus Bevacizumab updates RSS · CI watch RSS
- Tae Won Kim portfolio CI